Die FDA bietet keinen selbst aktualisierenden News-Dienst an, Informationen über aktuelle FDA-Zulassungen können auf der FDA-Homepage eingesehen werden.

Der kommerzielle Anbieter drugs.com publiziert einen Nachrichtendienst mit Informationen zu allen Neuzulassungen der FDA.

• FDA Approves Onswik (insulin efsitora alfa-gobe) Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
  24.09.2026
  INDIANAPOLIS, Sept. 24, 2026 /PRNewswire/ — Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), […]
• FDA Approves Lyrfigtu (lirafugratinib) for the Treatment of Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
  24.09.2026
  FORT LEE, N.J., September 23, 2026 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to […]
• FDA Approves Inluriyo (imlunestrant) in Combination with Verzenio (abemaciclib) for Adults with ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
  18.09.2026
  INDIANAPOLIS, Sept. 18, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted full […]
• IntraBio Announces U.S. FDA Approval of Aqneursa (levacetylleucine) for Ataxia-Telangiectasia
  18.09.2026
  AUSTIN, Texas–(BUSINESS WIRE) September 18, 2026 –IntraBio Inc., a leader in the discovery, development, and commercialization of novel therapies for rare and common neurodegenerative diseases, […]
• FDA Approves Fayuvi (rebisufligene etisparvovec-hopf) Gene Therapy for the Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
  18.09.2026
  NOVATO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) granted standard […]